The 32nd Annual Prostate Cancer Foundation Scientific Retreat Report
The Prostate · 17.11.2026
DOI: 10.1002/pros.70276 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Prostate, online erschienen am 17.11.2026. Verfasst von Andrea K Miyahira und 1 weiteren Autor:innen. Beteiligte Einrichtung: Medical & Science Department, Prostate Cancer Foundation, Santa Monica, California, USA. Die Arbeit nennt 115 Literaturangaben. Gefördert von: PCF, Prostate Cancer Foundation.
Abstract (Originalsprache)
Background
The 32nd Annual Prostate Cancer Foundation (PCF) Scientific Retreat took place in Carlsbad, CA on October 23–25, 2025.
Methods
The Annual PCF Scientific Retreat is a global forum for presenting the newest basic, translational, and clinical discoveries in prostate cancer, alongside work from related fields. Presentations highlight discoveries with strong potential to advance prostate cancer understanding, change clinical practice, and improve patient outcomes.
Results
The 2025 PCF Retreat featured research and special lectures from many disciplines, including: (i) next‐generation theranostics; (ii) emerging immunotherapy approaches in prostate cancer; (iii) understanding and drugging the epigenome; (iv) clinical trial updates; (v) artificial intelligence (AI) and machine learning; (vi) circulating biomarkers; (vii) harnessing the host microbiome in cancer; (viii) exercise interventions for patients with prostate cancer; (ix) CYP17A1‐independent androgen biosynthesis as a mechanism of persistent androgen production; (x) Prostate Cancer Working Group 4 recommendations for trial design and response assessment; (xi) tissue‐guided optimization of combination therapy; (xii) PCF Women in Science Lifetime Achievement Award lecture; and (xiii) bridging biomedical research and drug development.
Conclusions
The 2025 PCF Scientific Retreat illustrated how advances across diverse fields, including theranostics, immunotherapy, epigenetics, AI, and liquid biopsy, are converging to reshape how prostate cancer is understood, monitored, and treated. Recurring themes included tumor heterogeneity and lineage plasticity as determinants of treatment response, the need for predictive biomarkers to guide increasingly intensive and combination therapies, and the movement of effective therapies into earlier disease settings. This report reflects the state of the science as of October 2025.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical & Science Department, Prostate Cancer Foundation, Santa Monica, California, USA.
ORCID-Profile: Andrea K Miyahira
Förderung
- PCF
- Prostate Cancer Foundation
Zitieren
APA
Miyahira, A. K., & Koo, P. J. (2026). The 32nd Annual Prostate Cancer Foundation Scientific Retreat Report. The Prostate. https://doi.org/10.1002/pros.70276
Vancouver
Miyahira AK, Koo PJ. The 32nd Annual Prostate Cancer Foundation Scientific Retreat Report. The Prostate. 2026. doi:10.1002/pros.70276
BibTeX
@article{Miyahira2026,
author = {Miyahira, Andrea K and Koo, Phillip J},
title = {The 32nd Annual Prostate Cancer Foundation Scientific Retreat Report},
journal = {The Prostate},
year = {2026},
doi = {10.1002/pros.70276}
}
EUVIMED